Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
michael.desborough@linacre.ox.ac.uk
michael.desborough@ouh.nhs.uk

Address
Department of Clinical Haematology, Churchill Hospital, Oxford, OX3 9DU

Pronouns
He/Him

Research groups

Desborough Group: Platelet disorders and transfusion

Colleges

Linacre College

Michael Desborough

BMedSci(Hons), MB ChB, FRCP, FRCPath, DPhil

Consultant Haematologist & Associate Professor of Haematology

The overarching aim of the research conducted by my group is to develop and trial new treatments for platelet disorders and finding alternatives to platelet transfusion.

This includes trials of reversing antiplatelet drugs in intracerebral haemorrhage
Optimising treatment of fetal and neonatal alloimmune thrombocytopenia (FNAIT)
Clinical trials in transfusion medicine and immunohaematology [thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenia (ITP), warm autoimmune haemolytic anaemia (wAIHA), cold agglutinin disease (CAD)]
Developing the evidence base for platelet transfusion and alternatives to transfusion

Key publications

Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial.
Desborough MJR. et al, (2023), Lancet Neurol, 22, 557 - 567
Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials.
Odutayo A. et al, (2017), Lancet Gastroenterol Hepatol, 2, 354 - 360
Current practice and registration patterns among United Kingdom Haemophilia Centre Doctors' Organisation centers for patients with unclassified bleeding disorders.
Thomas W. et al, (2021), J Thromb Haemost
Drug-induced thrombotic thrombocytopenic purpura: A systematic review and review of European and North American pharmacovigilance data.
Schofield J. et al, (2022), Br J Haematol
Real-World Evidence of Caplacizumab Use in the Management of Acute TTP.
Dutt T. et al, (2020), Blood

Recent publications

Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial.
TREATT Trial Investigators None., (2025), Lancet Haematol, 12, e14 - e22
Hypercoagulation after Hospital Discharge in Acute Severe Ulcerative Colitis: A Prospective Study.
Griffiths BJ. et al, (2024), Clin Gastroenterol Hepatol
Myocardial iron intake following intravenous iron therapy with ferric carboxymaltose is sustained at 1 year despite recurrence of iron deficiency.
Piechnik SK. et al, (2024), Br J Haematol
Transfusion Camp: The UK experience and its value in improving knowledge of transfusion medicine among postgraduate trainees.
Aggarwal A. et al, (2024), Transfus Med
Intravenous iron therapy results in rapid and sustained rise in myocardial iron content through a novel pathway.
Vera-Aviles M. et al, (2024), Eur Heart J

More publications

ORCID

0000-0002-1951-5616